1. Consensus conference: Osteoporosis. JAMA 1984;252:799–802.
2. Silverman SL. The clinical consequences of vertebral compression fracture. Bone 1992;13(Suppl 2): S27–31.
3. Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998;128:793–800.
4. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41.
7. Rizzoli R, Greenspan SL, Bone G 3rd, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17:1988–96.
11. Oh Y, Wakabayashi Y, Kurosa Y, Fujita K, Okawa A. Potential pathogenic mechanism for stress fractures of the bowed femoral shaft in the elderly: mechanical analysis by the CT-based finite element method. Injury 2014;45:1764–71.
12. Yamazaki T, Takahashi K, Bessho K. Recent clinical evidence in bisphosphonate-related osteomyelitis of the jaw: focus on risk, prevention and treatment. Rev Recent Clin Trials 2014;9:37–52.
13. Zhang L, Pang Y, Shi Y, et al. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Menopause 2015;22:1021–5.
18. Chen Z, Lin W, Zhao S, et al. Effect of Teriparatide on pain relief, and quality of life in postmenopausal females with osteoporotic vertebral compression fractures, a retrospective cohort study. Ann Palliat Med 2021;10:4000–7.
19. Eriksen EF, Diez-Perez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone 2014;58:126–35.
20. Kong M, Zhou C, Zhu K, et al. 12-Month teriparatide treatment reduces new vertebral compression fractures incidence and back pain and improves quality of life after percutaneous kyphoplasty in osteoporotic women. Clin Interv Aging 2019;14:1693–703.
21. Tome-Bermejo F, Pinera AR, Alvarez-Galovich L. Osteoporosis and the management of spinal degenerative disease (I). Arch Bone Jt Surg 2017;5:272–82.
22. Ouyang Y, Chen S, Wan T, Zheng G, Sun G. The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: a protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e24839.
23. Gou PG, Zhao ZH, Zhou JM, et al. Vertebral collapse prevented following teriparatide treatment in postmenopausal Kummell’s disease patients with severe osteoporosis. Orthop Surg 2021;13:506–16.
28. Ma Y, Wu X, Xiao X, et al. Effects of teriparatide versus percutaneous vertebroplasty on pain relief, quality of life and cost-effectiveness in postmenopausal females with acute osteoporotic vertebral compression fracture: a prospective cohort study. Bone 2020;131:115154.